Detail akcie Grnwich LifeSci Rg online

Business Summary: Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Greenwich Lifesciences Inc revenues was not reported. Net loss increased 48% to $11.4M. Higher net loss reflects Research and development increase of 42% to $9.6M (expense), General and administrative increase of 65% to $1.9M (expense), Interest income decrease of 62% to $67K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.60 to -$0.85.